Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of chemotherapy-induced cardiomyopathy
IRCT20240126060818N1Phase 3Completed
- Sponsor
- Aja University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of empagliflozin in chemotherapy-induced cardiomyopathy (CICM), sponsored by Aja University of Medical Sciences. Started Mar 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
chemotherapy-induced cardiomyopathy (CICM)
Beyond the preview
Go deeper on IRCT20240126060818N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240126060818N1.